Company’s ThermoVax® platform has demonstrated protection against potentially lethal Ebola viruses Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharma company focused on developing and commercializing products…
[Read More]
Lexaria Bioscience (Nasdaq: LEXX) (Nasdaq: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers…
[Read More]
SPCB Shares Rise 62% on $33 Million National Electronic Monitoring Contract in EU With news that SuperCom (NASDAQ: SPCB), a global provider of secured solutions…
[Read More]
Following the receipt of Scientific Advice from the European Medicines Agency (EMA), specialty pharmaceutical company, Quoin Pharmaceuticals (Nasdaq: QNRX), has a clear path forward for…
[Read More]
After publishing the results of a recent study evaluating its HyBryte™ treatment for early-stage cutaneous T-cell lymphoma, Soligenix, Inc. (Nasdaq: SNGX) saw its shares jump…
[Read More]
With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia (“FM”), Virios Therapeutics (Nasdaq: VIRI) anticipates Phase 2b…
[Read More]
Newly uplisted biotech, ProMIS Neurosciences (Nasdaq: PMN)(TSX: PMN), soared on its first day of trading on Nasdaq, on Friday 8 July, closing up 44%. ProMIS…
[Read More]
In a significant step forward for rare disease treatment, Quoin Pharmaceuticals announced the opening of the first clinical site for its Netherton Syndrome study. The…
[Read More]
Biotechnology company, Oxford BioDynamics (AIM:OBD), is poised for successful commercialization of its precision medicine tests for oncology. Any seasoned investor will tell you that investing…
[Read More]
Key commercial and regulatory milestones expected during the second half of 2022 In a recent interview, Shameze Rampertab, CFO of Asensus Surgical (NYSE American: ASXC),…
[Read More]
Shared Reserves, Not Expenses Verde Bio Holdings (OTCQB: VBHI) is a trusted oil and gas mineral acquisition and management company based in Texas with acquisition…
[Read More]
While cutaneous T-cell lymphoma or CTCL—a rare form of non-Hodgkin’s lymphoma— currently has no FDA-approved first-line therapies, small-cap biotech Soligenix (Nasdaq: SNGX) is moving toward…
[Read More]